FinDogFinDog
Wednesday, September 16, 2026Closing data · 4:00 PM ET
English
Log in
FinDog Earnings CheckupEarnings release 08-04 · 10-Q 08-04Data from SEC filings

IDEXX Q2 FY26: revenue up 9.7%, EPS $4.27, guidance midpoint nudged higher

IDEXX delivered a genuinely strong quarter: revenue of $1.22 billion rose 9.7% as reported and 9.0% organic, gross margin reached 64.0%, and operating margin hit 35.0%. The $4.27 EPS beat the $4.0205 consensus, but $0.14 of it came from a share-based-compensation tax benefit, so the quality is lower than the headline suggests. Our read is Bullish, with cash conversion and the guidance mix as the details to watch.

1 · Expected vs. Actual

Free preview below
EPS (non-GAAP)
Beat
$4.07
Est. $4.02 · +1.2%

Diluted EPS of $4.27 rose 18% year over year and beat the $4.0205 consensus, but comparable EPS was $4.07 — a beat of roughly $0.05. The gap is $0.14 per share of share-based-compensation tax benefits plus a $0.06 currency tailwind. Strip those out and this is a solid, not spectacular, quarter.

Revenue
$1.22B
No consensus · YoY +9.7%

Revenue of $1.22 billion rose 9.7% as reported and 9.0% organic from $1.11 billion a year ago, with Companion Animal Group up 9.4% reported and Water up 14.8%. The recurring core — CAG Diagnostics recurring revenue — grew 11.0% reported, and IDEXX VetLab consumables grew 14.7%. The blemish is capital instruments, down 19.5% as last year's launch comparison rolls off.

Next-quarter revenue guidance
$4.72B ±0.5%
No consensus · YoY +288.2%

Full-year revenue guidance narrowed to $4,700 million-$4,745 million, up $5 million at the midpoint, and EPS guidance rose $0.14 at the midpoint to $14.69-$14.94. The revenue midpoint rose despite a $15 million currency headwind, reflecting better CAG Diagnostics recurring revenue. Note the shape: the low end rose and the high end came down.

Members Only

Log in to read 5 analyses a week for free

Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.

Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17

Ask About This Report

Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.

Log in to ask a question.